IGF-1: Your 24-Hour Read on Growth Hormone Activity

IGF-1, defined as a growth hormone messenger

IGF-1 is a hormone produced mainly by the liver after it receives a signal from growth hormone (GH), which is released by the pituitary gland. Think of GH as the signal and IGF-1 as the downstream action. Because GH spikes in short pulses while IGF-1 holds steady over 24 hours, IGF-1 serves as a stable, day-to-day proxy for GH activity — but it does not measure GH directly. It circulates in the blood and helps regulate growth, tissue repair, and metabolism. Higher IGF-1 generally reflects stronger GH activity or robust nutrition; lower levels often point to energy deficits, liver issues, thyroid changes, or the expected decline that comes with aging.

How growth hormone signals through IGF-1

The basic loop works like this: the pituitary gland pulses out GH, especially during deep sleep. The liver responds by producing IGF-1. IGF-1 then feeds back to the brain to keep GH in check. In the bloodstream, IGF-1 partners with binding proteins — particularly IGFBP-3 — that extend its half-life and regulate where it acts.

Poor sleep, stress hormones, or inflammatory signals can reduce the liver's responsiveness to GH, pulling IGF-1 down. Adequate calories and protein, stable thyroid function, and balanced sex hormones support IGF-1 production. During infections or inflammatory flares, cytokines can create hepatic GH resistance — lowering circulating IGF-1 independent of how much GH the pituitary is actually producing — and levels typically recover once the underlying illness resolves.

Training adds another layer. A hard resistance session can spike GH acutely, but circulating IGF-1 won't swing wildly hour to hour. Local IGF-1 signaling in muscle tissue can rise even when the blood level barely moves, which is one reason patterns over weeks matter more than a single post-workout draw. It is also worth noting that a serum IGF-1 result does not reflect local tissue IGF-1 signaling — it captures only what is circulating in the blood.

Reading your IGF-1 result by age and sex

Every lab provides a reference interval representing the middle range of results among otherwise healthy people of the same age and sex. IGF-1 ranges are strongly age-dependent: levels rise during puberty, peak in late adolescence, and gradually decline across adulthood. They also differ by sex and shift with life stage — pregnancy, for example, often increases IGF-1 due to placental growth hormone, while oral estrogen in non-pregnant adults can lower it through hepatic first-pass effects. Different assay platforms and calibration methods yield different numerical ranges, so results from different labs are not directly comparable.

Observational data suggest a U-shaped association with outcomes: both very high and very low IGF-1 levels have been linked to higher risks of issues such as cancer or frailty, depending on context. That doesn't translate to a single universal "best" number — it argues for personalized interpretation that accounts for age, symptoms, and goals.

When levels run high

Elevated IGF-1 can reflect strong GH activity, calorie and protein abundance, or the specific reference interval of the lab used. In athletes with adequate fueling, higher-but-still-in-range values can be physiologic. Persistently high values — especially above the lab's upper limit — raise the question of whether the pituitary is producing excess GH. Symptoms such as enlarging hands or feet, jaw changes, headaches, or new-onset snoring would increase suspicion for acromegaly, and an oral glucose suppression test for GH plus pituitary imaging may follow per endocrine guidelines. Thyroid status, liver function, and sex hormones can also tilt IGF-1 upward and change the picture.

When levels run low

Lower IGF-1 can be entirely expected with age, energy deficits, or recovery from illness. It can also signal reduced GH output from the pituitary or reduced hepatic responsiveness to GH. Malnutrition, significant calorie restriction, and low protein intake commonly push IGF-1 down. So do hypothyroidism, chronic liver disease, and high glucocorticoid exposure. In uncontrolled diabetes, the liver can become resistant to GH, which may lower IGF-1 until metabolic control improves. If someone presents with low IGF-1 alongside fatigue, low bone density, or reduced muscle mass, clinicians may consider GH deficiency testing — not based on IGF-1 alone, but with standardized stimulation tests and the full clinical picture.

Sleep, protein, training, and other IGF-1 levers

Several modifiable and non-modifiable factors can shift an IGF-1 result, and understanding them helps distinguish a meaningful change from background noise.

Protein and energy availability

IGF-1 responds to energy and protein availability. When the liver senses adequate calories and essential amino acids, it increases IGF-1 production. Prolonged calorie restriction or chronic underfueling tends to push IGF-1 down. Dairy and other high-quality proteins have been linked with modest IGF-1 increases in research, likely reflecting their amino acid profile and insulinotropic effect. Zinc deficiency can also depress IGF-1; correcting the deficiency tends to restore it. The consistent thread is adequacy rather than any single food or supplement.

Exercise and training load

Resistance training and mixed-modal activity influence the GH–IGF-1 axis over time. Acute GH peaks after exercise don't always translate into large swings in circulating IGF-1, but repeated training with sufficient recovery can support steady, appropriate levels. Overtraining, illness, or sleep debt can nudge IGF-1 down until the stress abates. Strict training combined with low energy availability can also lower it.

Sleep and stress

Deep sleep is when GH pulses peak. Chronic sleep loss blunts that rhythm and can reduce IGF-1 over time. Stress hormones and inflammatory cytokines signal the liver to prioritize defense over growth, creating transient GH resistance and pulling IGF-1 down during infections or inflammatory flares.

Hormones, medications, and medical conditions

Oral estrogens often lower IGF-1 via hepatic first-pass effects, while transdermal estrogen routes have a smaller impact. Androgens can raise IGF-1. Glucocorticoids tend to reduce it. Poorly controlled diabetes may lower it until glycemic control improves. Chronic liver disease reduces production and complicates interpretation. Thyroid status matters too — hypothyroidism can pull IGF-1 down by reducing hepatic GH responsiveness.

Biotin interference

High-dose biotin supplementation can interfere with certain immunoassays and produce falsely high or low IGF-1 results. Pausing high-dose biotin supplementation several days before a draw is recommended to avoid this artifact.

Pairing IGF-1 with the right hormone markers

IGF-1 rarely tells the whole story on its own. The following markers are particularly useful for contextualizing an unexpected result:

• TSH — hypothyroidism suppresses IGF-1 by reducing hepatic GH responsiveness; an unexpectedly low IGF-1 warrants TSH alongside it to rule out thyroid as the driver.
• ALT — IGF-1 is made by the liver; elevated ALT flags hepatocellular stress that can reduce IGF-1 production independent of GH output.
• Fasting glucose — uncontrolled diabetes creates hepatic GH resistance and can lower IGF-1; fasting glucose contextualizes an unexpectedly suppressed result.
• hs-CRP — systemic inflammation drives GH resistance in the liver; hs-CRP helps distinguish inflammation-driven IGF-1 suppression from a pituitary or nutritional issue.
• Total testosterone — both IGF-1 and testosterone support muscle and bone; pairing them reveals whether a frailty or recovery signal reflects GH-axis or androgen-axis disruption.

A realistic retest window for IGF-1

IGF-1 is stable throughout the day, so no fasting is required and the time of draw does not meaningfully affect the result. When tracking a lifestyle or nutritional intervention — such as improving protein intake, normalizing sleep, or repleting calories after a deficit — allow 8–12 weeks before retesting, as the axis responds over weeks rather than days. With GH therapy, the response window can begin as early as 4 weeks, though 8–12 weeks remains a reasonable standard interval for assessing a stable new level.

Because numerical ranges differ by assay platform and cannot be cross-compared, use the same lab and the same assay method for serial measurements. Before any draw, pause high-dose biotin supplementation for several days, as biotin interference with certain immunoassays can produce falsely high or low results.

When IGF-1 belongs with an endocrinologist

IGF-1 is stable enough to trend and sensitive enough to reflect real physiology. For prevention, it can flag when chronic stress, underfueling, or endocrine shifts are beginning to affect recovery. For medical evaluation, it is a cornerstone in screening for excess or deficient GH activity. A persistently elevated IGF-1 — especially with symptoms such as jaw or hand changes, headaches, or new snoring — warrants endocrine evaluation for acromegaly, including GH suppression testing and pituitary imaging. A low IGF-1 paired with fatigue, reduced bone density, or muscle loss may prompt GH deficiency workup using standardized stimulation tests alongside the full clinical picture. In either case, IGF-1 is a screening tool, not a standalone diagnosis.

For longevity and performance contexts, IGF-1 is most useful as one signal among many — tracked alongside thyroid, liver, glucose control, inflammation, and sex hormones to reveal how your systems are working together. With careful testing, method-aware interpretation, and collaboration with a qualified clinician, it becomes a meaningful part of your health picture rather than a one-off number. Superpower is built on that approach: connecting biomarkers to context so your results tell a coherent story.